Meniere Disease

Back

Author

R Gentry Wilkerson, MD, Clinical Assistant Professor, Department of Emergency Medicine, State University of New York-Downstate; Attending Physician, Department of Emergency Medicine, Kings County Hospital

Nothing to disclose.

Coauthor(s)

Christopher I Doty, MD, FACEP, FAAEM, Assistant Professor of Emergency Medicine, Residency Program Director, Department of Emergency Medicine, Kings County Hospital Center, State University of New York Downstate Medical Center

Nothing to disclose.

Specialty Editor(s)

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine

eMedicine Salary Employment

J Stephen Huff, MD, Associate Professor, Emergency Medicine and Neurology, Department of Emergency Medicine, University of Virginia Health Sciences Center

Nothing to disclose.

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

Nothing to disclose.

Mark S Slabinski, MD, FACEP, FAAEM, Vice President, EMP Medical Group

Nothing to disclose.

Chief Editor

Rick Kulkarni, MD, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital

WebMD Salary Employment

Background

Ménière's disease, also known as idiopathic endolymphatic hydrops, is a disorder of the inner ear resulting in the clinical triad of vertigo, tinnitus and hearing loss. Prosper Ménière first proposed the disorder in 1861 in a series of papers in which he rejected the term apoplectic cerebral congestion, commonly used for vertigo, as this suggested that the pathology lay in the brain. He initially proposed the term inner ear glaucoma.[1, 2, 3, 4] Patients report an intermittent and progressive nature of the disease with a significant number having spontaneous resolution.

Pathophysiology

The exact cause of Ménière's disease is controversial. The underlying mechanism is believed to be distortion of the membranous labyrinth due to overaccumulation of endolymph.

Endolymph is produced primarily by the stria vascularis in the cochlea and also by the planum semilunatum and the dark cells in the vestibular labyrinth.[5]

Endolymphatic flow has been previously described as a "lake-river-pond" model. The endolymph flows from the endolymphatic fluid space (lake) through the vestibular aqueduct (river) to the endolymphatic sac (pond).[6] If there is obstruction, then endolymphatic hydrops will occur.

Various extrinsic mechanisms are thought to contribute to the development of endolymphatic hydrops including infection, trauma, and allergens.[7]

Recent studies have questioned whether endolymphatic hydrops is a marker of disease rather than a cause. One study looking at temporal bones found all cases of patients with Ménière’s disease had hydrops in at least one ear. Hydrops was also found in patients who exhibited no signs of the disease.[8]

Epidemiology

Frequency

Reported prevalence of Ménière's disease varies widely, from 15 per 100,000 in the United States to 157 per 100,000 in the United Kingdom.[3] This difference in prevalence based on geographic area is likely due to reporting biases and not geographic patterns of disease.

Bilateral disease is found in 10% of patients with Ménière's disease at initial diagnosis but, with disease progression, it may increase to over 40%.[9]

A genetic predisposition appears to exist.[10]

Mortality/Morbidity

Mortality is not directly associated with Ménière's disease; however, the disease is associated with drop attacks, which could lead to accidental trauma resulting in morbidity or mortality.

The main morbidity associated with Ménière's disease is the debilitating nature of vertigo and the progressive and possibly permanent loss of hearing. In a Finnish study using a questionnaire, 22% of respondents listed problems with mobility and 19% listed mental effects of their illness.[11]

Race

Ménière's disease primarily affects Caucasians,[12] although this may be due to a reporting bias.[13]

Sex

A slight increase may be noted in females compared to males (1.3:1).[3] This may be biased due to more females seeking treatment.

Age

The peak incidence of Ménière's disease is in the 40- to 60-year-old age group.[3]

Ménière's disease has been described in children as young as 4 years and in elderly persons older than 90 years.[6]

History

The American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNS) Committee on Hearing and Equilibrium published guidelines on the clinical diagnosis of Ménière's disease in 1972, 1985, and, most recently, in 1995. According to these guidelines, Ménière's disease is defined as "recurrent, spontaneous episodic vertigo; hearing loss; aural fullness; and tinnitus. Either tinnitus or aural fullness (or both) must be present on the affected side to make the diagnosis."[14]

Physical

A complete neurological examination is necessary to differentiate Ménière's disease from other conditions.

Evaluation of vertigo

Dix-Hallpike positional test (also known as Nylen-Bárány maneuver) is performed.[18]

The Romberg test reveals significant instability during acute attacks.

Hennebert's sign is nystagmus owing to applied pressure in the external auditory canal.[3]

Tullio phenomenon is sound-induced vertigo, nystagmus, or both.[19] It is historically associated with syphilis but has been described in Ménière's disease.

Evaluation of hearing loss

Gross evaluation can be performed by gently rubbing the examiner's fingers near the patient's ears. The farthest distance the sound can be heard should be noted for each ear.

Rinne test performed with a 256-MHz tuning fork indicates that air conduction is greater than bone conduction.

Weber test is also performed with a 256-MHz tuning fork. Normally, sound should be heard equally on both sides. The sound is more pronounced on the affected side in middle ear disease or blockage of the external auditory canal. The sound is more pronounced on the unaffected side if there is cochlear nerve dysfunction.

Audiologic testing is more accurate.

Causes

Multiple causes of dysfunction of the vestibular system are known.

No single entity is known to be responsible for Ménière's disease. It is currently thought to be due to overaccumulation of endolymph in the cochlear duct.

Ménière's disease must be distinguished from other causes of endolymphatic hydrops such as post-traumatic, post-infectious, otosyphilis, and Cogan's syndrome (interstitial keratitis).[20]

An autoimmune etiology has been postulated after it was found that there was an association with presence of thyroid autoantibodies in patients with Ménière's disease.[21, 22]

Laboratory Studies

No laboratory test is specific for Ménière's disease.

Laboratory tests should be directed at differentiating Ménière's disease from other causes based on associated symptoms:

Imaging Studies

A patient with a history classic for Ménière's disease does not normally need imaging studies performed. If there is concern for other processes, then MRI or CT can be obtained based on the differential diagnosis.

MRI of the brain is used to detect abnormal inner ear anatomy, masses, and lesions such as multiple sclerosis and Arnold-Chiari malformations.[23]

CT scans are used to detect dehiscence of the superior semicircular canals, widened cochlear and vestibular aqueducts, and subarachnoid hemorrhage. While CT scans are useful at imaging the anatomy of temporal bone structures, specific findings and their association with Ménière's disease is a matter of debate.[24]

Other Tests

More extensive testing is typically reserved for outpatient or inpatient workup and is not performed in the emergency department:

Procedures

Most procedures are reserved for patients who have undergone extensive workup by an otolaryngologist and in whom conservative medical management has failed.

Surgical therapy for Ménière's disease as a last resort includes the following:

A Cochrane review article, recently, concluded that there is insufficient evidence to support endolymphatic sac surgery for the treatment of Ménière's disease.[30]

Emergency Department Care

The diagnosis of Ménière's disease is based on history and clinical findings. Most care in the emergency department is based on symptomatic relief of the clinical findings.

Consultations

Medication Summary

Medical treatment of Ménière's disease is aimed at symptomatic relief. The primary target is relief of vertiginous symptoms.[32] Antiemetics may be used for nausea and vomiting. A trial of intramuscular steroid injection followed by a tapering dose of oral steroids has been recommended.[31] Diuretics are often used, but their efficacy has not been established with appropriate clinical trials. Loop diuretics should be used with caution due to the potential for ototoxicity. Vasodilators, such as betahistine, have been used for the treatment of vertigo but are not FDA approved for this indication. They are thought to act by increasing circulatory flow to the cochlear stria vascularis[33] or through inhibition of vestibular nuclei activity.[34] Transtympanic steroid injection has been shown to be beneficial in controlling loss of hearing and the number of vertigo attacks.[35]

Class Summary

These agents are extremely useful in treating vertigo symptoms.

Meclizine (Antivert)

Clinical Context:  Decreases the excitability of the middle ear labyrinth and blocks conduction in the middle ear vestibular-cerebellar pathways. These effects are associated with its therapeutic effects in vertigo.

Dimenhydrinate (Dramamine)

Clinical Context:  Used for treatment and prophylaxis of vestibular disorders that may cause nausea and vomiting. Through its central anticholinergic activity, it diminishes vestibular stimulation and depresses labyrinthine function.

Class Summary

These agents are thought to work centrally by suppressing conduction in the vestibular cerebellar pathways.

Scopolamine (Isopto)

Clinical Context:  Blocks action of acetylcholine at parasympathetic sites and antagonizes histamine and serotonin action. Transdermal scopolamine may be the most effective agent for motion sickness. Use in the treatment of vestibular neuronitis is limited by its slow onset of action.

Class Summary

By binding to specific receptor sites, these agents appear to potentiate the effects of gamma-aminobutyric acid (GABA) and to facilitate inhibitory GABA neurotransmission and other inhibitory transmitters. These effects may offer benefits in the treatment of vertigo and emesis.

Diazepam (Valium)

Clinical Context:  Depresses all levels of the CNS, including limbic and reticular formation, possibly by increasing GABA activity, which is a major inhibitory neurotransmitter.

Class Summary

These agents are useful in treating emesis.

Promethazine (Phenergan)

Clinical Context:  Antidopaminergic agent effective in the treatment of emesis. Blocks postsynaptic mesolimbic dopaminergic receptors in the brain and reduces stimuli to the brainstem reticular system.

Prochlorperazine (Compazine)

Clinical Context:  Antidopaminergic drug that blocks the postsynaptic mesolimbic dopaminergic receptors. Has an anticholinergic effect and can depress the reticular activating system.

IV administration is not recommended for children.

Class Summary

These agents are useful in treating vertigo, but their mechanism of action is unclear.

Ephedrine (Pretz-D, Kondon's Nasal)

Clinical Context:  Stimulates the release of epinephrine stores producing alpha- and beta-adrenergic effects.

Class Summary

These agents have anti-inflammatory properties and cause profound and varied metabolic effects. No trials evaluating the efficacy of systemic steroids for the treatment of Ménière's disease have been done.[36]

Prednisone (Sterapred)

Clinical Context:  Useful in the treatment of inflammatory and allergic reactions. By reversing increased capillary permeability and suppressing PMN activity, it may decrease inflammation.

Class Summary

These agents are used for treating emesis.

Metoclopramide (Reglan)

Clinical Context:  Dopamine antagonist that stimulates acetylcholine release in the myenteric plexus. Acts centrally on chemoreceptor triggers in the floor of the fourth ventricle, which provides important antiemetic activity.

Further Inpatient Care

Patients with Ménière's disease require admission only if the symptoms are severe and refractory to medical management.

Further Outpatient Care

Inpatient & Outpatient Medications

Medications that provide symptomatic relief in the emergency department should be considered for use on an outpatient basis.

Deterrence/Prevention

Quality evidence is lacking regarding deterrence and prevention of acute attacks of Ménière's disease; however, the following suggestions are often made:

Complications

Complications of Ménière's disease may include the following:

Prognosis

Patient presentation and progression of disease vary widely. Periods of remission punctuated by exacerbations of symptoms are typical for the disease.[38] Some have minimal symptoms, whereas others have severe attacks. Episodes may occur as infrequently as once or twice a year or they may occur on a regular basis.

The spontaneous remission rate is high at over 50% within 2 years and over 70% after 8 years.[3]

Most of the remainder are well managed with medications.

Surgical treatment is required for 5-10% of patients.

References

  1. Meniere P. Observations de maladies de I'oreille interne caracterisee par des symptomesde congestion apoplectiforme. Gaz Med de Paris. 1861;16:379.
  2. Meniere P. Maladies de l'oreille interne offrant les symptomes de la congestion cerebraleapoplectiforme. Gaz Med de Paris. 1861;16:88.
  3. Minor LB, Schessel DA, Carey JP. Ménière's disease. Curr Opin Neurol. Feb 2004;17(1):9-16.[View Abstract]
  4. Meniere P. Nouveaux documents relatifs aux lesions de l'oreille interne caracterisee pardes symptomes de congestion cerebrale apoplectiforme. Gaz Med de Paris. 1861;16:239.
  5. Sajjadi H, Paparella MM. Meniere's disease. Lancet. Aug 2 2008;372(9636):406-14.[View Abstract]
  6. Paparella MM. Pathogenesis and pathophysiology of Meniére's disease. Acta Otolaryngol Suppl. 1991;485:26-35.[View Abstract]
  7. Paparella MM, Djalilian HR. Etiology, pathophysiology of symptoms, and pathogenesis of Meniere's disease. Otolaryngol Clin North Am. Jun 2002;35(3):529-45, vi.[View Abstract]
  8. Merchant SN, Adams JC, Nadol JB Jr. Pathophysiology of Meniere's syndrome: are symptoms caused by endolymphatic hydrops?. Otol Neurotol. Jan 2005;26(1):74-81.[View Abstract]
  9. Kitahara M. Bilateral aspects of Meniére's disease. Meniére's disease with bilateral fluctuant hearing loss. Acta Otolaryngol Suppl. 1991;485:74-7.[View Abstract]
  10. Klockars T, Kentala E. Inheritance of Meniere's disease in the Finnish population. Arch Otolaryngol Head Neck Surg. Jan 2007;133(1):73-7.[View Abstract]
  11. Stephens D, Pyykko I, Varpa K, Levo H, Poe D, Kentala E. Self-reported effects of Ménière's disease on the individual's life: a qualitative analysis. Otol Neurotol. Feb 2010;31(2):335-8.[View Abstract]
  12. Morrison AW, Johnson KJ. Genetics (molecular biology) and Meniere's disease. Otolaryngol Clin North Am. Jun 2002;35(3):497-516.[View Abstract]
  13. Mancini F, Catalani M, Carru M, Monti B. History of Meniere's disease and its clinical presentation. Otolaryngol Clin North Am. Jun 2002;35(3):565-80.[View Abstract]
  14. Monsell EM. New and revised reporting guidelines from the Committee on Hearing and Equilibrium. American Academy of Otolaryngology-Head and Neck Surgery Foundation, Inc. Otolaryngol Head Neck Surg. Sep 1995;113(3):176-8.[View Abstract]
  15. Baloh RW, Jacobson K, Winder T. Intratympanic gentamicin for Meniere's disease: effect on quality of life as assessed by Glasgow benefit inventory. J Laryngol Otol. Oct 2006;120(10):827-31.[View Abstract]
  16. Kentala E, Havia M, Pyykko I. Short-lasting drop attacks in Meniere's disease. Otolaryngol Head Neck Surg. May 2001;124(5):526-30.[View Abstract]
  17. Bhattacharyya N, Baugh RF, Orvidas L, Barrs D, Bronston LJ, Cass S. Clinical practice guideline: benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg. Nov 2008;139(5 Suppl 4):S47-81.[View Abstract]
  18. White J. Benign paroxysmal positional vertigo: how to diagnose and quickly treat it. Cleve Clin J Med. Sep 2004;71(9):722-8.[View Abstract]
  19. Bronstein A. Visual symptoms and vertigo. Neurol Clin. Aug 2005;23(3):705-13, v-vi.[View Abstract]
  20. Grasland A, Pouchot J, Hachulla E, Bletry O, Papo T, Vinceneux P. Typical and atypical Cogan's syndrome: 32 cases and review of the literature. Rheumatology (Oxford). Aug 2004;43(8):1007-15.[View Abstract]
  21. Fattori B, Nacci A, Dardano A, Dallan I, Grosso M, Traino C. Possible association between thyroid autoimmunity and Menière's disease. Clin Exp Immunol. Apr 2008;152(1):28-32.[View Abstract]
  22. Nacci A, Dallan I, Monzani F, Dardano A, Migliorini P, Riente L. Elevated antithyroid peroxidase and antinuclear autoantibody titers in Ménière's disease patients: more than a chance association?. Audiol Neurootol. 2010;15(1):1-6.[View Abstract]
  23. Lorenzi MC, Bento RF, Daniel MM, Leite CC. Magnetic resonance imaging of the temporal bone in patients with Ménière's disease. Acta Otolaryngol. Aug 2000;120(5):615-9.[View Abstract]
  24. de Sousa LC, Piza MR, da Costa SS. Diagnosis of Meniere's disease: routine and extended tests. Otolaryngol Clin North Am. Jun 2002;35(3):547-64.[View Abstract]
  25. Smith WK, Sandooram D, Prinsley PR. Intratympanic gentamicin treatment in Meniere's disease: patients' experiences and outcomes. J Laryngol Otol. Sep 2006;120(9):730-5.[View Abstract]
  26. Banerjee AS, Johnson IJ. Intratympanic gentamicin for Ménière's disease: effect on quality of life as assessed by Glasgow benefit inventory. J Laryngol Otol. Oct 2006;120(10):827-31.[View Abstract]
  27. Hsieh LC, Lin HC, Tsai HT, Ko YC, Shu MT, Lin LH. High-dose intratympanic gentamicin instillations for treatment of Meniere's disease: long-term results. Acta Otolaryngol. Dec 2009;129(12):1420-4.[View Abstract]
  28. Barrs DM. Intratympanic corticosteroids for Meniere's disease and vertigo. Otolaryngol Clin North Am. Oct 2004;37(5):955-72, v.[View Abstract]
  29. Wetmore SJ. Endolymphatic sac surgery for Ménière's disease: long-term results after primary and revision surgery. Arch Otolaryngol Head Neck Surg. Nov 2008;134(11):1144-8.[View Abstract]
  30. Pullens B, Giard JL, Verschuur HP, van Benthem PP. Surgery for Ménière's disease. Cochrane Database Syst Rev. Jan 20 2010;CD005395.[View Abstract]
  31. Sajjadi H. Medical management of Meniere's disease. Otolaryngol Clin North Am. Jun 2002;35(3):581-9, vii.[View Abstract]
  32. Coelho DH, Lalwani AK. Medical management of Ménière's disease. Laryngoscope. Jun 2008;118(6):1099-108.[View Abstract]
  33. Phillips JS, Prinsley PR. Prescribing practices for Betahistine. Br J Clin Pharmacol. Apr 2008;65(4):470-1.[View Abstract]
  34. Mira E, Guidetti G, Ghilardi L, Fattori B, Malannino N, Maiolino L. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. Eur Arch Otorhinolaryngol. Feb 2003;260(2):73-7.[View Abstract]
  35. Herraiz C, Plaza G, Aparicio JM, Gallego I, Marcos S, Ruiz C. Transtympanic steroids for Ménière's disease. Otol Neurotol. Jan 2010;31(1):162-7.[View Abstract]
  36. Cope D, Bova R. Steroids in otolaryngology. Laryngoscope. Sep 2008;118(9):1556-60.[View Abstract]
  37. Odkvist LM, Arlinger S, Billermark E, Densert B, Lindholm S, Wallqvist J. Effects of middle ear pressure changes on clinical symptoms in patients with Ménière's disease--a clinical multicentre placebo-controlled study. Acta Otolaryngol Suppl. 2000;543:99-101.[View Abstract]
  38. Havia M, Kentala E. Progression of symptoms of dizziness in Ménière's disease. Arch Otolaryngol Head Neck Surg. Apr 2004;130(4):431-5.[View Abstract]